

# Right-Sided Lesions/Interval Cancers and Surveillance after Colorectal Neoplasia

WEO CRC SC Expert Working Groups – Joint Session

---

**Thursday, April 22, 2021 – 6.00 pm (CEST, Berlin, Amsterdam)**

Corresponding Pacific Time: 9.00 am

Corresponding Eastern Time: 12.00 pm/Noon

**Chairs:** Matthew Rutter, Jeffrey Lee (Right-Sided-Lesions/Interval Cancers)  
Rodrigo Jover, Uri Ladabaum (Surveillance after Colorectal Neoplasia)

**Session Title:** Reducing post-colonoscopy disease burden – updates on PCCRC and post-polypectomy surveillance.

Webinar via Zoom Webinars, registered participants will receive link for meeting.

---

## Webinar Program (CEST)

- |         |   |   |
|---------|---|---|
| 6.00 pm | Welcome by Expert Working Group Co-Chairs   | <i>Matthew Rutter (UK) and<br/>Jeffrey Lee (USA)</i>    |
| 6.05 pm | Is there a role of an interval FIT for the prevention of PCCRC? incl. discussion  | <i>Han-Mo Chiu (Taiwan)</i>                             |
| 6.20 pm | Are PCCRCs more lethal compared to detected CRCs?<br><br>The view from Sweden<br>The view from Canada   | <i>Anna Forsberg (Sweden)<br/>Fahima Dossa (Canada)</i> |
| 6.40 pm | Discussion  |   |
| 6.55 pm | Break (5 minutes)   |   |
| 7.00 pm | Welcome by Expert Working Group Co-Chairs   | <i>Rodrigo Jover (Spain), Uri Ladabaum (USA)</i>        |
| 7.05 pm | Systematic review and meta-analysis on surveillance after excision of high-risk adenomas.   | <i>Sandra Baile-Maxia (Spain)</i>                       |
| 7.25 pm | Are we successfully reducing CRC risk in patients with baseline High Risk Adenomas? Review and active discussion:<br>Please come prepared to discuss and brainstorm on potential future collaborative research:<br><br>1) What does the elevated future CRC risk <u>despite HRA removal</u> mean in patients with baseline HRA? | <i>Uri Ladabaum (USA)</i>                               |

- 2) Can we do better at baseline colonoscopy?  
Implications for surveillance?
- 3) How much of surveillance in these patients is aimed  
at early CRC detection vs. CRC prevention?
- 4) Research ideas / proposals? What datasets /  
populations / resources are available?

8.00 pm Meeting adjourns

---

**We would like to thank the following partners for their support:**

 **alfresa**

Alfresa Pharma Corporation

 **EIKEN CHEMICAL**

 **Polymedco, Inc.**

**SENTINEL**  
DIAGNOSTICS